Bayer Signs $25 Million License Agreement With US Company to Develop Breast Cancer Drug
15 Settembre 2020 - 2:39PM
Dow Jones News
By Cecilia Butini
Bayer AG said Tuesday that it has entered a license agreement
with U.S.-based biotechnology company Systems Oncology LLC to
develop and commercialize its breast cancer drug ERSO with an
upfront payment of $25 million.
Under the agreement, the German chemical and pharmaceutical
conglomerate will also grant Systems Oncology commercialization
milestone payments for a total of $345 million, it said, plus
payments upon achievement of certain development and royalties on
future global net sales.
ERSO is a compound currently in pre-clinical development which
can be used for the treatment of metastatic Estrogen
Receptor-positive breast cancer, Bayer said.
It added that the drug could represent a novel treatment option
for patients with this type of cancer, given that there are only
limited options available so far for patients with progressed forms
of the disease.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
September 15, 2020 08:24 ET (12:24 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Apr 2023 a Apr 2024
